In particular, CYP2C9 metabolizes arachidonic acid to the following eicosatrienoic acid epoxide (EETs) stereoisomer sets: 5"R",6"S"-epoxy-8Z,11Z,14Z-eicosatetrienoic and 5"S",6"R"-epoxy-8Z,11Z,14Z-eicosatetrienoic acids; 11"R",12"S"-epoxy-8Z,11Z,14Z-eicosatetrienoic and 11"S",12"R"-epoxy-5Z,8Z,14Z-eicosatetrienoic acids; and 14"R",15"S"-epoxy-5Z,8Z,11Z-eicosatetrainoic and 14"S",15"R"-epoxy-5Z,8Z,11Z-eicosatetrainoic acids. It likewise metabolizes docosahexaenoic acid to epoxydocosapentaenoic acids (EDPs; primarily 19,20-epoxy-eicosapentaenoic acid isomers 10,11-EDPs) and eicosapentaenoic acid to epoxyeicosatetraenoic acids (EEQs, primarily 17,18-EEQ and 14,15-EEQ isomers). Animal models and a limited number of human studies implicate these epoxides in reducing hypertension; protecting against myocardial infarction and other insults to the heart; promoting the growth and metastasis of certain cancers; inhibiting inflammation; stimulating blood vessel formation; and possessing a variety of actions on neural tissues including modulating neurohormone release and blocking pain perception (see epoxyeicosatrienoic acid and epoxygenase).